title: In vitro effects of meloxicam on the number, Foxp3 expression, production of selected cytokines, and apoptosis of bovine CD25+CD4+ and CD25-CD4+ cells.
abstract: The purpose of this study was to evaluate the effect of meloxicam (MEL) on selected immune parameters of bovine CD25(high)CD4+, CD25(low)CD4+, and CD25-CD4+ cells. Peripheral blood mononuclear cells (PBMCs) collected from 12-month-old heifers were treated with MEL at a concentration corresponding to the serum level of this medication following administration at the recommended dose (MEL 5 × 10(⁻6) M) and at a concentration 10 times lower (MEL 5 × 10(⁻7) M). After 12 and 24 h of incubation with the drug, the percentage of CD25(high)CD4+ cells decreased; however, this disturbance was quickly reversed. Furthermore, the absolute number of CD25(high)CD4+ cells in the PBMC populations treated with MEL 5 × 10(⁻6) M for 48 and 168 h was increased. Prolonged (168 h) exposure to the drug increased the percentage of Foxp3+ cells in the CD25(high)CD4+ cell subpopulation. The higher dose of MEL was found to significantly increase the percentage of IFN-γ+ cells among the CD25-CD4+ cells. These results indicated that MEL does not exert an immunosuppressive effect by depleting CD4+ cells and suppression of IFN-γ+ production by these cells. Furthermore, IL-10 and TGF-β production was not changed following exposure to MEL.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Olsztyn 10-718, Poland. tomasz.maslanka@uwm.edu.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Maślanka
authors.forename: Jerzy Jan
authors.initials: JJ
authors.lastname: Jaroszewski
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D002417:Cattle; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D051858:Forkhead Transcription Factors / Q000235:genetics* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects*; D007108:Immune Tolerance / Q000187:drug effects; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D000077239:Meloxicam; D013843:Thiazines / Q000008:administration & dosage / Q000494:pharmacology*; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D051858:Forkhead Transcription Factors; D053645:Interleukin-2 Receptor alpha Subunit; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam
keywords: CD4+ cells; Foxp3; cattle; cytokines; meloxicam